Encompass Health Corporation, based in Birmingham, Alabama, is the nation's largest provider of inpatient rehabilitative services, offering facility-based care through its network of 166 inpatient rehabilitation hospitals located in 38 states and Puerto Rico. Encompass Health's hospitals focus on providing rehabilitative treatment and care to patients who are recovering from stroke and other neurological disorders, cardiac and pulmonary conditions, brain and spinal cord injuries, complex orthopedic conditions and amputations. The company operated a home health and hospice business that was spun off as Enhabit in 2022.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| EHC | Encompass Health Corp | 2026-04-02 16:22:00 | 97.39 | 0 | 0 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EHC | 0000785161 | Encompass Health Corp | US29261A1007 | 549300FVRPM9DRQZRG64 | 630860407 | NYSE | 8060 | Services-Hospitals | 1231 | DE | 9001 LIBERTY PARKWAY | BIRMINGHAM | AL | 35242 | UNITED STATES | US | 205-967-7116 | 9001 LIBERTY PARKWAY, BIRMINGHAM, AL, 35242 | 9001 LIBERTY PARKWAY, BIRMINGHAM, AL, 35242 | HEALTHSOUTH CORP | Healthcare | 1984 | Mark Tarr | 40,200 | http://encompasshealth.com | 12,200,000,000 | 116,036,500 | 99,416,162 | Encompass Health Corporation, based in Birmingham, Alabama, is the nation's largest provider of inpatient rehabilitative services, offering facility-based care through its network of 166 inpatient rehabilitation hospitals located in 38 states and Puerto Rico. Encompass Health's hospitals focus on providing rehabilitative treatment and care to patients who are recovering from stroke and other neurological disorders, cardiac and pulmonary conditions, brain and spinal cord injuries, complex orthopedic conditions and amputations. The company operated a home health and hospice business that was spun off as Enhabit in 2022. | 2026-04-02 16:00:48 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2025 | 12,200,000,000 | 3,700,000,000 | 43.5294 | 99,416,162 | -1,292,944 | -1.2838 |
| 2024 | 8,500,000,000 | 1,800,000,000 | 26.8657 | 100,709,106 | 569,075 | 0.5683 |
| 2023 | 6,700,000,000 | 1,200,000,000 | 21.8182 | 100,140,031 | 412,609 | 0.4137 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Patrick Darby | Secretary, Executive Vice President, General Counsel | 2024 | 625,000 | 0 | 923,376 | 792,797 | 11,500 | 2,558,994 |
| Elissa J. Charbonneau | Chief Medical Officer | 2024 | 415,000 | 0 | 501,762 | 350,945 | 23,880 | 1,291,587 |
| Mark J. Tarr | Chief Executive Officer, President | 2024 | 1,050,000 | 0 | 4,856,982 | 2,131,038 | 178,621 | 9,301,929 |
| Douglas E. Coltharp | Chief Financial Officer, Executive Vice President | 2024 | 700,000 | 0 | 1,723,516 | 1,006,324 | 53,776 | 3,868,736 |
| Andrew L. Price | Chief Accounting Officer | 2024 | 345,000 | 0 | 417,186 | 291,749 | 19,577 | 1,073,512 |
| Fiscal Year | Employee Count |
|---|---|
| 2025 | 42,000 |
| 2024 | 40,000 |
| 2023 | 38,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | 5,935,200,000 | 5,373,200,000 | 4,801,200,000 |
| Cost Of Revenue | — | — | — |
| Gross Profit | — | — | — |
| Research And Development Expenses | — | — | — |
| General And Administrative Expenses | 236,200,000 | 209,200,000 | 201,700,000 |
| Operating Expenses | 4,882,100,000 | 4,508,700,000 | 4,069,400,000 |
| Operating Income | — | — | — |
| Net Income | 566,200,000 | 455,700,000 | 352,000,000 |
| Earnings Per Share Basic | 5.62 | 4.53 | 3.51 |
| Earnings Per Share Diluted | 5.54 | 4.46 | 3.47 |
| Weighted Average Shares Outstanding Basic | 100,500,000 | 99,900,000 | 99,500,000 |
| Weighted Average Shares Outstanding Diluted | 102,200,000 | 102,200,000 | 101,300,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash And Cash Equivalents | 72,200,000 | 85,400,000 | 69,100,000 |
| Marketable Securities Current | — | — | — |
| Accounts Receivable | 619,200,000 | 598,800,000 | 611,600,000 |
| Inventories | — | — | — |
| Non Trade Receivables | — | — | — |
| Other Assets Current | 129,900,000 | 122,700,000 | 91,500,000 |
| Total Assets Current | 905,900,000 | 886,900,000 | 841,800,000 |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | — | — | — |
| Other Assets Non Current | 243,700,000 | 219,200,000 | 191,600,000 |
| Total Assets Non Current | 6,183,800,000 | 5,647,800,000 | 5,260,600,000 |
| Total Assets | 7,089,700,000 | 6,534,700,000 | 6,102,400,000 |
| Accounts Payable | 178,200,000 | 171,000,000 | 170,000,000 |
| Deferred Revenue | — | — | — |
| Short Term Debt | 43,600,000 | 138,600,000 | 24,800,000 |
| Other Liabilities Current | 289,600,000 | 238,600,000 | 187,400,000 |
| Total Liabilities Current | 836,400,000 | 841,000,000 | 656,400,000 |
| Long Term Debt | 2,447,200,000 | 2,359,200,000 | 2,687,800,000 |
| Other Liabilities Non Current | 53,800,000 | 51,800,000 | 46,100,000 |
| Total Liabilities Non Current | 2,977,500,000 | 2,844,500,000 | 3,148,800,000 |
| Total Liabilities | 3,813,900,000 | 3,685,500,000 | 3,805,200,000 |
| Common Stock | 1,200,000 | 1,200,000 | 1,200,000 |
| Retained Earnings | 1,289,400,000 | 796,700,000 | 406,500,000 |
| Accumulated Other Comprehensive Income | 500,000 | — | — |
| Total Shareholders Equity | 2,438,200,000 | 2,067,000,000 | 1,647,500,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Depreciation And Amortization | 327,900,000 | 299,600,000 | 273,900,000 |
| Share Based Compensation Expense | 56,500,000 | 48,300,000 | 50,600,000 |
| Other Non Cash Income Expense | 3,500,000 | -14,700,000 | -5,200,000 |
| Change In Accounts Receivable | 15,200,000 | -3,000,000 | 22,400,000 |
| Change In Inventories | — | — | — |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | — | — | — |
| Change In Accounts Payable | -22,600,000 | 3,000,000 | 11,800,000 |
| Change In Other Liabilities | 57,400,000 | 52,800,000 | 15,600,000 |
| Cash From Operating Activities | 1,175,600,000 | 1,002,800,000 | 850,800,000 |
| Purchases Of Marketable Securities | — | — | — |
| Sales Of Marketable Securities | 32,300,000 | — | — |
| Acquisition Of Property Plant And Equipment | 736,400,000 | 642,500,000 | 583,100,000 |
| Acquisition Of Business | — | — | 0 |
| Other Investing Activities | 16,600,000 | 7,200,000 | -3,300,000 |
| Cash From Investing Activities | -764,600,000 | -653,300,000 | -602,800,000 |
| Tax Withholding For Share Based Compensation | 20,000,000 | 12,100,000 | 8,200,000 |
| Payments Of Dividends | 73,300,000 | 65,100,000 | 60,700,000 |
| Issuance Of Common Stock | — | — | — |
| Repurchase Of Common Stock | 158,000,000 | 31,100,000 | — |
| Issuance Of Long Term Debt | 210,000,000 | 80,000,000 | 60,000,000 |
| Repayment Of Long Term Debt | — | — | — |
| Other Financing Activities | -2,800,000 | 2,100,000 | 1,200,000 |
| Cash From Financing Activities | -431,200,000 | -330,600,000 | -197,200,000 |
| Change In Cash | -20,200,000 | 18,900,000 | 50,800,000 |
| Cash At End Of Period | 72,200,000 | 85,400,000 | 69,100,000 |
| Income Taxes Paid | 124,000,000 | 164,500,000 | 109,300,000 |
| Interest Paid | 133,100,000 | 146,800,000 | 147,700,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Earnings Per Share | 5.62 | 4.53 | 3.51 |
| Price To Earnings Ratio | 18.8861 | 20.3863 | 19.0085 |
| Earnings Growth Rate | 24.0618 | 29.0598 | 29.0441 |
| Price Earnings To Growth Ratio | 0.7849 | 0.7015 | 0.6545 |
| Book Value Per Share | 32.595 | 28.5205 | 23.0874 |
| Price To Book Ratio | 3.2563 | 3.238 | 2.8899 |
| Ebitda | 1,141,300,000 | 1,057,200,000 | 878,700,000 |
| Enterprise Value | 13,085,670,000 | 11,638,165,000 | 9,282,140,000 |
| Dividend Yield | 0.0069 | 0.0071 | 0.0091 |
| Dividend Payout Ratio | 0.1295 | 0.1429 | 0.1724 |
| Debt To Equity Ratio | 1.0216 | 1.2084 | 1.6465 |
| Capital Expenditures | — | — | — |
| Free Cash Flow | — | — | — |
| Return On Equity | 0.2322 | 0.2205 | 0.2137 |
| One Year Beta | 0.4759 | 0.5187 | 0.4975 |
| Three Year Beta | 0.4888 | 0.667 | 0.673 |
| Five Year Beta | 0.6053 | 0.8071 | 0.8308 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Fay Edmund | Sr. Vice Pres. and Treasurer | 2026-03-09 | 11,937 | D | 89,325 |
| Fay Edmund | Sr. Vice Pres. and Treasurer | 2026-03-09 | 3,000 | D | 86,325 |
| COLTHARP DOUGLAS E | EVP & Chief Financial Officer | 2026-03-02 | 12,275 | A | 12,275 |
| Tuer Patrick William | EVP, Chief Operating Officer | 2026-03-02 | 10,502 | A | 10,502 |
| Tarr Mark J | Director, President & CEO | 2026-03-02 | 35,461 | A | 35,461 |
| Name Of Reporting Person | Report Date | State | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| Lisa McClain | 2025-11-21 | MI09 | Purchase | 2025-10-30 | Spouse | $1,001 - $15,000 |
| Lisa McClain | 2025-11-21 | MI09 | Sale | 2025-10-30 | Spouse | $1,001 - $15,000 |
| Lisa McClain | 2025-11-21 | MI09 | Sale | 2025-10-31 | Spouse | $1,001 - $15,000 |
| Lisa McClain | 2025-08-13 | MI09 | Purchase | 2025-07-22 | Spouse | $1,001 - $15,000 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| Ares Financial Consulting, LLC | 2026-03-31 | 3,798 | 39 | 97.3846 |
| GOLDMAN SACHS GROUP INC | 2025-12-31 | 47,954,479 | 451,804 | 106.14 |
| HSBC HOLDINGS PLC | 2025-12-31 | 29,605,723 | 276,194 | 107.1918 |
| Rockefeller Capital Management L.P. | 2025-12-31 | 378,790 | 3,568 | 106.1631 |
| Corient Private Wealth LLC | 2025-12-31 | 1,858,840 | 17,496 | 106.2437 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| Direxion Shares ETF Trust | 2026-01-31 | Direxion Daily Mid Cap Bull 3X ETF | MIDU | 1,688 | 159,566.64 | 0.2095 |
| Pacer Funds Trust | 2026-01-31 | Pacer Trendpilot US Mid Cap ETF | PTMC | 11,756 | 1,111,294.68 | 0.2864 |
| INVESCO EXCHANGE-TRADED FUND TRUST | 2026-01-31 | Invesco S&P MidCap Momentum ETF | XMMO | 440,395 | 41,630,539.35 | 0.7977 |
| AIM INVESTMENT FUNDS (INVESCO INVESTMENT FUNDS) | 2026-01-31 | Class R | GTHRX | 143,359 | 13,551,726.27 | 1.1011 |
| AIM INVESTMENT FUNDS (INVESCO INVESTMENT FUNDS) | 2026-01-31 | Class Y | GGHYX | 143,359 | 13,551,726.27 | 1.1011 |